Understanding deficient elimination of uric acid

The Lancet

Volumn 372, Issue 9654, 2008, Pages 1929-1930

  Aringer, Martin ^a   Graessler, Juergen ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BREAST CANCER RESISTANCE PROTEIN; COTRANSPORTER; FEBUXOSTAT; PROTEIN SLC17A3; PROTEIN SLC2A9; UNCLASSIFIED DRUG; URIC ACID;

ALLELE; ARTICLE; DIET RESTRICTION; DNA POLYMORPHISM; GOUT; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR; URIC ACID BLOOD LEVEL; URINARY EXCRETION;

EID: 57049110975     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61344-6     Document Type: Note

References (11)

1. Martinon F., Petrilli V., Mayor A., Tardivel A., and Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 (2006) 237-241
2. Pechey J. The whole works of that excellent physician, Dr Thomas Sydenham. 7th edn. (1717), M Wellington, London 341-353
3. Enomoto A., Kimura H., Chairoungdua A., et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417 (2002) 447-452
4. Graessler J., Graessler A., Unger S., et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 54 (2006) 292-300
5. Vitart V., Rudan I., Hayward C., et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 40 (2008) 437-442
6. Doring A., Gieger C., Mehta D., et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 40 (2008) 430-436
7. Wallace C., Newhouse S.J., Braund P., et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet 82 (2008) 139-149
8. Dehghan A., Köttgen A., Yang Q., et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet (2008) 10.1016/S0140-6736(08)61343-4 published online Oct 1
9. Sundy J.S., Ganson N.J., Kelly S.J., et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 56 (2007) 1021-1028
10. Zhang W., Doherty M., Bardin T., et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65 (2006) 1312-1324
11. Becker M.A., Schumacher Jr. H.R., Wortmann R.L., et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 52 (2005) 916-923